Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027960 (mole)
 21,279 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Implementation of the new arsenic MCL in 2006 will lead to the generation of an estimated 6 million pounds of arsenic-bearing solid residuals (ABSRs) every year, which will be disposed predominantly in non-hazardous landfills. The Toxicity Characteristic Leaching Procedure (TCLP) is typically used to assess whether a waste is hazardous and most solid residuals pass the TCLP. However, recent research shows the TCLP significantly underestimates arsenic mobilization in landfills. A variety of compositional dissimilarities between landfill leachates and the TCLP extractant solution likely play a role. Among the abiotic factors likely to play a key role in arsenic remobilization/leaching from solid sorbents are pH, and the concentrations of natural organic matter (NOM) and anions like phosphate, bicarbonate, sulfate and silicate. This study evaluates the desorption of arsenic from actual treatment sorbents, activated alumina (AA) and granular ferric hydroxide (GFH), which are representative of those predicted for use in arsenic removal processes, and as a function of the specific range of pH and concentrations of the competitive anions and NOM found in landfills. The influence of pH is much more significant than that of competing anions or NOM. An increase in one unit of pH may increase the fraction of arsenic leached by 3-4 times. NOM and phosphate replace arsenic from sorbent surface sites up to three orders of magnitude more than bicarbonate, sulfate and silicate, on a per mole basis. Effects of anions are neither additive nor purely competitive. Leaching tests, which compare the fraction of arsenic mobilized by the TCLP vis-a-vis an actual or more realistic synthetic landfill leachate, indicate that higher pH, and greater concentrations of anions and NOM are all factors, but of varying significance, in causing higher extraction in landfill and synthetic leachates than the TCLP.
 ...
PMID:Effect of pH, competitive anions and NOM on the leaching of arsenic from solid residuals. 1623 21

Conjunctival tumors encompass a broad range of diagnoses. The 3 most important malignant tumors include ocular surface squamous neoplasia (OSSN) (14%), melanoma (12%), and lymphoma (7%). Conjunctival malignancies are rarely found in children. Regarding OSSN, pre-disposing conditions include chronic solar radiation, immune deficiency (HIV), organ transplant, autoimmune conditions, xeroderma pigmentosum, and chronic exposure to cigarette smoke. OSSN is managed surgically or with topical/injection immunotherapy or chemotherapy. Metastasis occurs in <1%. Regarding melanoma, predisposing conditions include primary acquired melanosis (PAM), chronic nevus, and chronic solar radiation. Treatment of PAM or nevus can prevent melanoma. Melanoma management involves surgical resection with clean margins and avoidance of direct tumor manipulation ("no touch" technique). The first surgery is most important, to minimize tumor seeding. Biomarkers including BRAF, TERT, and PTEN provide information regarding risk for metastasis and allow for targeted antibiomarker therapies. Ten-year risk for melanoma metastasis is 25%. Tumors >2 mm thickness or those located in fornix, caruncle, or orbit are at highest risk for metastasis. Regarding lymphoma, predisposing conditions include benign reactive lymphoid hyperplasia, immune deficiency (HIV), immune dysfunction, and chronic inflammation/infection (Helicobacter pylori, Chlamydia psittaci). The 4 most important subtypes include extranodal marginal zone lymphoma (ENMZL), follicular lymphoma, mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma. Treatment includes surgical resection, cryotherapy, radiotherapy, systemic chemotherapy, or targeted anti-B-cell therapy (rituximab). Lymphoma-related survival (5-year) depends on subtype and ranges from 97% (ENMZL) to 9% (MCL). Recognizing conjunctival tumors and understanding predisposing factors, biomarkers, and treatment strategies are vital to patient outcomes.
 ...
PMID:Conjunctival Tumors: Review of Clinical Features, Risks, Biomarkers, and Outcomes--The 2017 J. Donald M. Gass Lecture. 2839 47